Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat cancer and other serious diseases for which there is significant demand for new therapies. Our most advanced drug development candidate is TELCYTA™ (TLK286), a novel tumor activated compound which is currently in a Phase 3 registration trial in advanced ovarian cancer, and in Phase 2 trials in non-small cell lung, ovarian and breast cancer. A second product candidate, TLK199, is in a Phase 1-2a clinical trial for the treatment of myelodysplastic syndrome, a form of pre-leukemia, and also may be useful for increasing blood cell levels depleted by cancer chemotherapy. In addition to these and other products in our cancer pipeline, we are developing potential new treatments for Type 2 diabetes and inflammation. Our product candidates were discovered using our proprietary technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.